From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 1987
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.14
Pain Relevance 1.69

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde2a) signal transduction (Pde2a) Golgi apparatus (Pde2a)
endoplasmic reticulum (Pde2a) plasma membrane (Pde2a) nucleus (Pde2a)
Anatomy Link Frequency
respiratory 1
Pde2a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Neuropeptide 1 100.00 Very High Very High Very High
nociceptor 1 100.00 Very High Very High Very High
tolerance 9 98.04 Very High Very High Very High
Morphine 9 97.52 Very High Very High Very High
antinociception 2 96.84 Very High Very High Very High
depression 10 95.24 Very High Very High Very High
agonist 3 94.72 High High
opiate 1 94.04 High High
antagonist 1 93.76 High High
Hippocampus 9 74.52 Quite High
Disease Link Frequency Relevance Heat
Disease 7 99.96 Very High Very High Very High
Cognitive Disorder 94 99.26 Very High Very High Very High
Natriuresis 4 97.52 Very High Very High Very High
Catalepsy 2 96.16 Very High Very High Very High
Respiratory Failure 2 95.72 Very High Very High Very High
Mydriatic 1 94.64 High High
Reprotox - General 2 4 81.28 Quite High
Urological Neuroanatomy 1 72.20 Quite High
Cv Unclassified Under Development 1 69.20 Quite High
Coronary Heart Disease 20 46.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Differential effects of CGS 8216 and naltrexone on ingestional behaviour.
Regulation (effects) of CGS
1) Confidence 0.23 Published 1987 Journal Pharmacol. Biochem. Behav. Section Title Doc Link 3562485 Disease Relevance 0 Pain Relevance 0.19
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Regulation (Effect) of cyclic GMP-phosphodiesterase in respiratory associated with mydriatic, depression, morphine, antinociception, catalepsy, tolerance, neuropeptide and respiratory failure
2) Confidence 0.18 Published 1991 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 1653844 Disease Relevance 0.52 Pain Relevance 1.31
Consequently, when developing a PDE-I for the treatment of cognitive decline resulting from Alzheimer’s disease, PDE2-Is and PDE9-Is may be better targets in this population than PDE5-Is.
Regulation (targets) of PDE2 associated with cognitive disorder and disease
3) Confidence 0.10 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.28 Pain Relevance 0.16
On the other hand, various phosphodiesterases regulate cGMP catabolism, including PDE-5A, PDE-6, PDE-9A, PDE-10A, and PDE-11A according to their tissue specificity [21-23].
Regulation (regulate) of cGMP
4) Confidence 0.06 Published 2005 Journal BMC Pharmacol Section Body Doc Link PMC1131906 Disease Relevance 0.34 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools